| 摘要 |
The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab, including the use of a 420 mg fixed dosage form so as to extend measured time to disease progression or survival in breast cancer patients. |
